The purchase includes Tyrvaya, for the treatment of dry eye disease.
Tender offer to acquire all outstanding shares of Oyster Point Pharma for $11.00 per share, plus a contingent value right of up to $2.00 per share.
Get the most important news and business ideas for eyecare professionals every weekday from INVISION.
Tons of business ideas for eyecare professionals!
Advertisement